Rajshekhar Chakraborty, MD shares results from the LINKER-MM2 trial which assessed the safety and efficacy of #linvoseltamab plus #carfilzomib for patients with heavily pretreated relapsed/refractory #MM. Learn more:

According to results from a case series study, various total neoadjuvant therapy approaches demonstrated similar efficacy and safety outcomes among patients with locally advanced rectal cancer. Learn more: #medtwitter #onctwitter

Brain-directed stereotactic radiation demonstrated lower rates of neurologic death compared to whole-brain radiation among patients with #SCLC who have 1 to 10 brain metastases. Learn more: #medtwitter #onctwitter

Andrew Kuykendall, MD, discusses the results of the phase 3 VERIFY trial which compared #rusfertide vs placebo for certain patients with #myeloproliferative #neoplasms. Learn more:

An intensive trimodal therapy regimen showed a statistically significant improvement of overall survival among patients with anaplastic thyroid cancer, compared with those who received less intense therapy. Learn more: #medtwitter #onctwitter

Study results demonstrated that curative pencil beam scanning proton therapy demonstrated promising long-term efficacy and safety among children and adolescent/young adult patients with #chordomas or #chondrosarcomas. Learn more: #medtwitter #onctwitter

According to a real-world analysis, there was promising intracranial activity seen with trastuzumab deruxtecan among patients with HER2-positive or HER2-low, metastatic breast cancer with active brain metastases. Learn more: #medtwitter #onctwitter

According to final immunophenotypic and biomarker analysis results from the phase 2 #PAVE study, intercalated #avelumab plus #chemotherapy demonstrated promising efficacy and safety among patients with ES-SCLC. Learn more: . #medtwitter #onctwitter

Robert Bennett, PhD, RN, PPCNP-BC, CPNP-AC, discusses a study aiming to determine symbols of hope as described by Hispanic adolescent and young adult survivors of cancer. Learn more:

According to results from the phase 2 #AveRec trial, #avelumab following long-course chemoradiotherapy demonstrated clinical promise among patients with locally advanced, resectable rectal cancer. Learn more: #medtwitter #onctwitter

Experts debate third-line treatment options for patients with chronic #GVHD, exploring #axatilimab (#Niktimvo) vs other therapies in this 4-part video series. Learn more:

Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma. Learn more: #medtwitter #onctwitter

Benjamin Watkins, MD, shares the case of an 18-year-old male with relapsed AML who underwent a haploidentical peripheral blood stem cell transplant from his 40-year-old father following myeloablative conditioning with busulfan and fludarabine. Learn more:

According to results from the #CheckMate8HW trial, #nivolumab plus #ipilimumab significantly improved health-related quality of life compared to nivolumab alone among patients with MSI-H/dMMR mCRC. Learn more: #medtwitter #onctwitter

Peter Voorhees, MD, discusses long-term results from the CARTITDE-1 trial, which demonstrated durable and deep responses at 5 years following #ciltacabtagene autoleucel infusion among patients with heavily pretreated relapsed/refractory #MM. Learn more:

A study found that serum NRG1, NRG1 protein, and NRG1 mRNA in the tumor tissue prior to receiving ADT may predict the incidence of castration-resistant prostate cancer among patients with prostate cancer undergoing ADT. Learn more: #medtwitter #onctwitter

The European Commission has approved #ibrutinib with chemoimmunotherapy for the treatment of #MCL based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with current standard of care. Learn more:

Eric Christenson, MD, discusses results from a phase 2 clinical trial that highlighted the impact of nivolumab and relatlimab on the TME among previously treated patients with unresectable or metastatic pMMR CRC. Learn more: #medtwitter #onctwitter

At the 2025 ONS Congress, Nicole Ferreira, MSN, RN, NPD-BC, BMTCN, OCN shares the development of an oncology fellowship program aimed to improve specialized practitioner education and competence as well as decrease practice turnover. Learn more:

The @US_FDA granted accelerated approval to the protease activator #dordaviprone for the treatment of adult and pediatric patients with diffuse midline #glioma with an #H3K27M mutation and progressive disease after previous therapy. Learn more: